SCHEMBL8055652

SCHEMBL8055652

C[C@H]1NC(=O)N(c2cc(Cc3n[nH]c(=O)c4c3CCCC4)ccc2F)C1=O

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8050461 1.00 PARP1 (0.74) PARP1
SCHEMBL2208157 1.00 PARP1 (0.74) PARP1
SCHEMBL5131450 0.89 PARP1 (0.79) PARP1
SCHEMBL4439350 0.85 PARP1 (1.00) PARP1
SCHEMBL20544385 0.85 PARP1 (0.55) PARP1
SCHEMBL4436099 0.85 PARP1 (1.00) PARP1
SCHEMBL5095905 0.84 PARP1 (1.00) PARP1
SCHEMBL4555468 0.84 PARP1 (1.00) PARP1
SCHEMBL4440665 0.84 PARP1 (1.00) PARP1
SCHEMBL8242343 0.84 PARP1 (0.67) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981890-B2 Phthalazinone derivatives ASTRAZENECA AB (SE) 2011-07-19 US disclosed
US-7981890-B2 Phthalazinone derivatives ASTRAZENECA AB (SE) 2011-07-19 US disclosed
US-20090186897-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-07-23 US disclosed
US-20090186897-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-07-23 US disclosed
WO-2009034326-A1 PHTHALAZINONE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186897-A1 PHTHALAZINONE DERIVATIVES RCC2, CBR1, RCC1 PARP1 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.